Is QURE a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for QURE (QURE) rests on AMT-130 accelerated-approval path: The FDA has agreed that AMT-130's three-year Phase I/II data can serve as the primary basis for a BLA under the accelerated-approval pathway, and uniQure plans to submit in Q3 2026. Revenue (Q1 2026) is ~$3.6M (mostly license and royalty). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. Whether QURE is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

uniQure N.V. is a Netherlands-based, Nasdaq-listed clinical-stage biotech developing adeno-associated virus (AAV) gene therapies for serious central-nervous-system and other genetic diseases. Its lead program is AMT-130, a one-time gene therapy for Huntington's disease, delivered surgically into the brain, that met its primary endpoint at three years with roughly 75% slowing of disease progression versus external controls in a Phase I/II study. The rest of the pipeline is earlier stage: AMT-162 for SOD1 ALS, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease. The company already validated its platform once by developing Hemgenix, the hemophilia B gene therapy now commercialized by CSL Behring, which produces royalty income. The investment picture is that of a single-asset biotech. Product revenue is minimal (a few million dollars a quarter, mostly license and royalty income), and the company runs a large net loss funding R&D and commercial preparation. What matters is AMT-130: uniQure reached agreement with the FDA that its three-year data can support a Biologics License Application under the accelerated-approval pathway, with the submission planned for the third quarter of 2026 and a potential decision as early as mid-2027. Because Huntington's has no approved disease-modifying therapy and decades of prior failures, a first approval could be transformative, while a setback would remove most of the thesis. A cash balance of roughly $587 million funds operations into the second half of 2029, giving runway through the key regulatory events.

What's the case for buying QURE?

1. AMT-130 accelerated-approval path.

The FDA has agreed that AMT-130's three-year Phase I/II data can serve as the primary basis for a BLA under the accelerated-approval pathway, and uniQure plans to submit in Q3 2026. AMT-130 carries RMAT, Breakthrough Therapy, and Fast Track designations, and Huntington's has no approved disease-modifying treatment, so a first-to-market gene therapy would define the company's value.

2. First-mover position in Huntington's.

Competing programs from Roche/Ionis, Wave, PTC, and others are either earlier stage or have stumbled, most notably Roche's tominersen, which failed to show meaningful clinical benefit. That leaves uniQure ahead of the field with the most advanced disease-modifying candidate and strong three-year efficacy data, at least for now.

3. Pipeline and platform optionality.

Beyond Huntington's, uniQure has early clinical programs in SOD1 ALS (AMT-162), refractory temporal-lobe epilepsy (AMT-260), and Fabry disease (AMT-191), plus royalties from the already-approved hemophilia B gene therapy Hemgenix, commercialized by CSL Behring. These provide additional shots on goal and some validation of the AAV platform.

4. Funded through key catalysts.

uniQure held roughly $587 million in cash, equivalents, and investments as of the first quarter of 2026, which management projects funds operations into the second half of 2029. That runway covers the planned BLA submission and a potential approval decision without an immediate need to raise capital under pressure.

What are the risks to QURE?

uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. The accelerated-approval pathway still requires alignment with the FDA on a confirmatory study, and there is precedent for the agency demanding more evidence in neurology. The rest of the pipeline is early and unproven, so it offers limited support if the lead program falters. As a pre-profit company, uniQure burns tens of millions per quarter and will likely need to raise capital again, which can dilute shareholders, and the stock is highly volatile and prone to large swings around clinical and regulatory news. Competition in Huntington's is also intensifying as rival mechanisms advance.

How is QURE valued? (as of July 2026)

Price

$38.21

Market cap

$2.63B

Forward P/E

-13.48

Price / book

16.13

Beta

0.90

52-week range

$8.73 to $71.50

Snapshot for QURE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (Q1 2026): ~$3.6M (mostly license and royalty)
Net loss (Q1 2026): ~$53.5M (~$0.85 per share)
R&D expense (Q1 2026): ~$29M
Cash and investments: ~$587M (into 2H 2029 runway)
Share price: ~$39 (late July 2026)
Market cap: ~$1.0-2.0B (moves sharply on news)

uniQure is pre-profit, so traditional valuation multiples like P/E do not apply and the stock is valued on the probability-weighted potential of its pipeline, chiefly AMT-130. Product revenue is minimal, with most of the small top line coming from Hemgenix royalties and license deals, while the company runs large losses funding development. The large cash balance relative to the market cap is a distinguishing feature, giving runway through the planned Q3 2026 BLA submission and beyond.

How do you decide if QURE is a buy?

Rather than asking whether QURE is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold QURE indirectly through an index or sector ETF before adding more.

For the full picture, see the QURE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about QURE against your real portfolio and see your actual exposure before deciding.

The bottom line on QURE

The bottom line: QURE's story right now is AMT-130 accelerated-approval path, with revenue (q1 2026) at ~$3.6M (mostly license and royalty). If you believe that narrative continues, the call is about sizing QURE sensibly and checking overlap with what you own; if you doubt it (the risk: uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

FAQ

Is QURE a good stock to buy right now?

The case for QURE right now is AMT-130 accelerated-approval path, with revenue (q1 2026) at ~$3.6M (mostly license and royalty). If you believe that thesis holds, QURE is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does QURE do?

uniQure N.V.

What are the main risks of QURE?

What does uniQure do?

uniQure is a clinical-stage biotech that develops one-time AAV gene therapies for serious genetic and central-nervous-system diseases. Its lead program is AMT-130 for Huntington's disease, and it has earlier programs in ALS, epilepsy, and Fabry disease, plus royalties from the approved hemophilia B therapy Hemgenix.

Why is QURE considered a high-risk stock?

Most of uniQure's value rests on a single asset, AMT-130. As a pre-profit biotech with minimal revenue and large losses, its share price swings sharply on clinical and regulatory news, so outcomes are unusually binary compared with a diversified, cash-flowing company.

What is AMT-130?

AMT-130 is uniQure's investigational one-time gene therapy for Huntington's disease, delivered surgically into the brain. In its Phase I/II study it met the primary endpoint at three years with roughly 75% slowing of disease progression versus external controls, and it holds RMAT, Breakthrough Therapy, and Fast Track designations.

When could AMT-130 be approved?

uniQure plans to submit a Biologics License Application to the FDA in the third quarter of 2026 under the accelerated-approval pathway, using its three-year data. With a rolling review, a decision could come as early as mid-2027, though timelines and outcomes are not guaranteed.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell QURE; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.